Brought to you by 
AstraZeneca spins out Albireo
17 Feb 2021
Executive Summary
AstraZeneca PLC has spun out its gastrointestinal therapeutics business into a new company called Albireo Pharmaceutical. AZ, along with Nomura Phase4 Ventures, TVM Capital, and Scottish Widows Investment Partnership, provided $27mm in funding to the new entity in a Series A round that is expected to reach $40mm in the near future.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Spin-Off
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AstraZeneca spins out Albireo
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice